Skip to main content

Table 2 Secondary outcomes reported

From: Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials

Trial name

Other adverse outcomes

Follow up period

DAPT use

DUTCH PEERS [17]

TVF, all-cause death, cardiac death, TVMI, any TVR, clinically indicated TVR, clinically indicated TLR, TLF, MACEs, patient-oriented composite endpoint

12 months

1 year

HOST-ASSURE [18]

TLF, all-cause death, cardiac death, TVMI, repeated revascularization, TLR, TVR, CVA, TVF, patient-oriented composite endpoint

12 months

1 year

Lin 2015 [15]

Adverse cardiac events, all-cause death, cardiac death, MI

15 months

1 year

Mehilli 2013 [16]

All-cause death, MI, stroke, TLR, patient-oriented composite endpoint

12 months

1 year

RESOLUTE [19]

TLR, all-cause death, cardiac death, TVMI, clinically indicated TLR, MI, clinically indicated TVR, MACEs, patient-oriented composite endpoint, TVF

12 months

6 months to 1 year

TWENTE [20]

TVF, all-cause death, cardiac death, TVMI, clinically indicated TVR, TLF, clinically indicated TLR, MACEs, patient-oriented composite endpoint

12 months

1 year

  1. TVF target vessel failure, TVMI target vessel related myocardial infarction, TVR target vessel revascularization, TLF target lesion failure, MACEs major adverse cardiac events, CVA cardiovascular accident, TVF target vessel failure, MI myocardial infarction, DAPT dual antiplatelet therapy